Pre-treatment 18F-RGD Uptake may Predict Adverse Events during Apatinib Antiangiogenic Therapy

•The adverse events during antiangiogenic therapy inevitably influence the quality of life, and no biomarkers were available to identify those high-risk patients.•Compared with the patients with high SUVmax, those patients with low RGD in liver, spleen and gastric cardia had statistically higher incidence of fatigue, hypertension and nausea during antiangiogenic therapy.•Those biomarkers to identify patients who will experience adverse events would be useful for high-risk patients to decrease the occurrence of antiangiogenic AEs by early intervention with drugs or physical treatment.